Purisys
United States 32 employees Updated 9 July 2026
Purisys is an API manufacturer based in United States. It holds 7 active US drug master files across a filed portfolio of 6 molecules. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 13 March 2024 as VAI.
1
registered plants
1 with an FDA FEI number
0
filings
across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Inspections
2 of 2 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.
Inspection history
- 13 March 2024 VAI US FDA
- 15 June 2017 NAI US FDA
NAI means no action indicated, VAI means voluntary action indicated, and OAI means
official action indicated.
Registered plants
| Site | FDA FEI |
| Athens, United States | 3012286613 |
What they file, and where
| Molecule | Regulators | Docs |
| Dronabinol | US FDA | 2 |
| Cannabidiol | US FDA | 1 |
| Dexmethylphenidate | US FDA | 1 |
| Nabilone | US FDA | 1 |
| Nalmefene | US FDA | 1 |
| Psilocybin | US FDA | 1 |
Also appears on these molecule pages
Filings and GMP by regulator
| Regulator | Filings | GMP certificates |
| US FDA | None | 1 |
Comparing suppliers?
Choose your molecules and target markets. Purisys comes back tiered against every other
supplier able to file there.
Start for free No sales call.
Open risk flags
- The most recent inspection outcome was VAI, on 13 March 2024.
Sources on this page
- FDA
- Drug master files, establishment registration, inspection classifications
- EDQM
- Certificates of suitability
- EudraGMDP and national regulators
- GMP certificates